Eli Lilly and Company Aktie News

Selpercatinib  demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on previous results for selpercatinib in advanced NSCLC and reinforce the value of genomic testing at diagnosis and across all stages of disease INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and...

Using artificial intelligence to create new drugs may be the technology's most important and marketable use. The idea isn't merely hypothetical anymore, either.

Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss.

Drug companies must continue to fill their pipelines. Lilly recently made three key deals.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Lilly agreed to purchase biotech Orna Therapeutics. Orna's drug candidate treats diseases in a novel way.

Following record-breaking adoption of its GLP-1 portfolio and positive Phase 3 data in Alzheimer's treatments, LLY has entered a new growth tier. Our multi-factor analysis suggests now is an opportune time to buy LLY stock.

Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.